Rankings
▼
Calendar
COLL Q2 2021 Earnings — Collegium Pharmaceutical, Inc. Revenue & Financial Results | Market Cap Arena
COLL
Collegium Pharmaceutical, Inc.
$1B
Q2 2021 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$83M
+6.3% YoY
Gross Profit
$50M
60.6% margin
Operating Income
$16M
19.8% margin
Net Income
$73M
87.8% margin
EPS (Diluted)
$1.79
QoQ Revenue Growth
-5.4%
Cash Flow
Operating Cash Flow
$30M
Free Cash Flow
$29M
Stock-Based Comp.
$7M
Balance Sheet
Total Assets
$714M
Total Liabilities
$461M
Stockholders' Equity
$253M
Cash & Equivalents
$203M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$83M
$78M
+6.3%
Gross Profit
$50M
$48M
+3.9%
Operating Income
$16M
$17M
-0.8%
Net Income
$73M
$8M
+804.0%
Revenue Segments
Nucynta
$50M
38%
Xtampza
$33M
25%
Nucynta Ir
$29M
22%
Nucynta Er
$21M
16%
← FY 2021
All Quarters
Q3 2021 →